Dr. Hampel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st Street SW
Rochester, MN 55905
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2018 - 2021- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2015 - 2018
University of Missouri-Columbia School of MedicineClass of 2015
Certifications & Licensure
MN State Medical License 2016 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.Paul J Hampel, Kari G Rabe, Yucai Wang, Steven R Hwang, Saad S Kenderian
Leukemia. 2024-12-10 - Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL).Aswin Sekar, Rosalie Griffin, Sameer A Parikh, Giulio Genovese, Dennis P Robinson
Blood Cancer Journal. 2024-11-06 - Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism.Amber B Koehler, Kari G Rabe, Daniel J Crusan, Timothy G Call, Sara J Achenbach
Journal of Thrombosis and Haemostasis. 2024-09-27
Journal Articles
- Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical CentreSameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology
Lectures
- BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
